Suppr超能文献

肠道生物标志物、微生物群组成以及炎症性肠病的遗传易感性作为帕金森病表现的预测指标。

Intestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation.

作者信息

Chai Zhi, Ouyang Yuxia, Debebe Anketse, Picker Mellissa, Lee Won-Jun, Fenton Seth, Becker-Dorison Anouck, Augustin-Emmerichs Kerstin, Schwiertz Andreas, Weber Susanne N, Lammert Frank, Hu Jianzhong, Fang Gang, Unger Marcus M, Peter Inga

机构信息

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

出版信息

J Parkinsons Dis. 2025 May 7:1877718X251328567. doi: 10.1177/1877718X251328567.

Abstract

BackgroundParkinson's disease (PD) is often accompanied by gastrointestinal symptoms. While elevated inflammatory biomarkers have been reported in PD patients compared to controls, the role of intestinal dysmotility and inflammation in disease manifestation is not fully understood.ObjectiveThis study sought to determine if fecal biomarkers and genetic predisposition to intestinal inflammation could help identify PD subtypes for future targeted therapies.MethodsThe association of disease activity, assessed through United Parkinson's disease Rating Scale (UPDRS) and Non-Motor Symptoms Questionnaire (NMSQ), with constipation severity, fecal calprotectin and six short-chain fatty acid (SCFA) levels, polygenic risk scores (PRS) for inflammatory bowel disease (IBD) and PD, and microbiota diversity were investigated in 95 participants with established PD using regression analyses. Unsupervised k-means clustering was applied to stratify PD patients based on inflammatory biomarkers.ResultsHaving constipation was linked to worse mentation (UPDRSI, adj. = 0.03) and more limited daily living activities (UPDRSII, adj. = 0.03), with symptom severity linearly associated with higher disease activity (UPDRSI, adj. = 0.002; NMSQ-total, adj. = 0.02). Fecal calprotectin was elevated in those with constipation ( = 0.02) and associated with longer disease duration irrespective of the age (adj. = 0.02). Cluster analysis demonstrated that PD patients with a higher non-motor symptom UPDRSII score were more likely to have more severe constipation, lower fecal SCFA levels, lower bacterial diversity, and higher PRS-CD and PRS-IBD.ConclusionsGut dysmotility, along with pro-inflammatory intestinal profiles, and greater genetic predisposition to IBD were observed in PD patients with worse non-motor symptoms. Monitoring intestinal biomarkers may help identify PD patients for targeted interventions.

摘要

背景

帕金森病(PD)常伴有胃肠道症状。虽然与对照组相比,PD患者的炎症生物标志物有所升高,但肠道运动障碍和炎症在疾病表现中的作用尚未完全明确。

目的

本研究旨在确定粪便生物标志物和肠道炎症的遗传易感性是否有助于识别PD亚型,以便未来进行靶向治疗。

方法

通过帕金森病统一评分量表(UPDRS)和非运动症状问卷(NMSQ)评估疾病活动度,研究95例确诊为PD的参与者便秘严重程度、粪便钙卫蛋白和六种短链脂肪酸(SCFA)水平、炎症性肠病(IBD)和PD的多基因风险评分(PRS)以及微生物群多样性之间的关联,采用回归分析方法。应用无监督k均值聚类根据炎症生物标志物对PD患者进行分层。

结果

便秘与较差的精神状态(UPDRSI,校正值=0.03)和更受限的日常生活活动(UPDRSII,校正值=0.03)相关,症状严重程度与较高的疾病活动度呈线性相关(UPDRSI,校正值=0.002;NMSQ总分,校正值=0.02)。便秘患者的粪便钙卫蛋白升高(P=0.02),且与疾病持续时间延长相关,与年龄无关(校正值=0.02)。聚类分析表明,非运动症状UPDRSII评分较高的PD患者更有可能出现更严重的便秘、较低的粪便SCFA水平、较低的细菌多样性以及较高的PRS-CD和PRS-IBD。

结论

在非运动症状较差的PD患者中观察到肠道运动障碍、促炎肠道特征以及对IBD的遗传易感性增加。监测肠道生物标志物可能有助于识别适合靶向干预的PD患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验